Research
Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo-controlled double-blind trial

https://doi.org/10.1016/0965-2299(93)90029-DGet rights and content

Abstract

The efficacy and tolerance of standardised celandine extract in the form of Gallopas 100 film-coated tablets were investigated in a placebo-controlled, double-blind trial on groups of 30 patients with functional epigastric complaints. Over the 6 week observation period, the only improvement in clinical findings was noted during treatment with the active drug. The distribution of the test findings showed a trend towards freedom from symptoms on Gallopas 100 for most of the symptoms. It was particularly noticeable that doctor and patients regarded the active medication as better tolerated than placebo. Inferential statistics validated the differences between Gallopas 100 and placebo in terms of efficacy and tolerance in respect of disorders of the gallbladder, biliary tract and pancreas.

References (11)

  • C Ley
  • E Teuscher et al.

    Biogene Gifte

  • JC Baumann et al.

    Klinischexperimentelle Untersuchungen der Gallen, Pankreas und Magensaftskretion under den phytocholagogen Wirkstoffen einer Carduus marianus-Chelidonium-Curcuma-Suspension

    Arzneimittelforschung

    (1971)
  • D Kupke et al.

    Prüfung der choleretischen Aktivität eines pflanzlichen Cholagogums

    Z Allg Med

    (1991)
  • AA Betterman

    Gallenbeschwerden: Rasche Hilf mit konservativer Therapie, Ergebnisse einer multizentrischen Feldstudie mit Chelidonin

    Arztliche Praxis

    (1980)
There are more references available in the full text version of this article.

Cited by (18)

  • Chelidonium majus crude extract inhibits migration and induces cell cycle arrest and apoptosis in tumor cell lines

    2016, Journal of Ethnopharmacology
    Citation Excerpt :

    Description and medicinal uses of this plant are monographed in the European Pharmacopoeia and in a national pharmacopoeia, and reported in well established documents (EMA/HMPC, 2011). A number of pharmacological properties, e.g. spasmolitic (Hiller et al., 1998), anti-inflammatory (Lee et al., 2007), antioxidant (Jakovljević et al., 2013), antiulcer (Khayyal et al., 2001), antibacterial (Zuo et al., 2008), antiviral (Gerencer et al., 2006), immunomodulatory (Chung et al., 2004; Song et al., 2002) and antitumor (Aljuraisy et al., 2012; Mahmoud et al., 2013) have been reviewed and supported by clinical data (Knöpfel, 1991; Ritter et al., 1993). By virtue of these properties C. majus is widely used in alternative medicine to treat liver diseases, gastric ulcer and spasm, oral infections, rheumatic diseases, tuberculosis and jaundice (Abu, 1956; Amirdowlat, 1990; Mills and Bone, 2000; Pelagić, 1893; Zadorozhnyj, 1990).

  • Complementary and Alternative Medicine

    2010, Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print
View all citing articles on Scopus
View full text